Oncopeptides Financials
| ONCO Stock | SEK 1.54 0.03 1.99% |
Oncopeptides |
Understanding current and past Oncopeptides Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Oncopeptides' financial statements are interrelated, with each one affecting the others. For example, an increase in Oncopeptides' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Oncopeptides' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Oncopeptides AB. Check Oncopeptides' Beneish M Score to see the likelihood of Oncopeptides' management manipulating its earnings.
Oncopeptides Stock Summary
Oncopeptides competes with Hansa Biopharma, BioArctic, Sinch AB, and Cantargia. Oncopeptides AB , a pharmaceutical company, develops drugs for the treatment of cancer. The company was founded in 2000 and is headquartered in Stockholm, Sweden. Oncopeptides is traded on Stockholm Stock Exchange in Sweden.| Foreign Associate | USA |
| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0009414576 |
| Business Address | Vastra Tradgardsgatan 15, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.oncopeptides.com/sv |
| Phone | 46 86 15 20 40 |
| Currency | SEK - Swedish Kronor |
You should never invest in Oncopeptides without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Oncopeptides Stock, because this is throwing your money away. Analyzing the key information contained in Oncopeptides' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Oncopeptides Key Financial Ratios
Oncopeptides' financial ratios allow both analysts and investors to convert raw data from Oncopeptides' financial statements into concise, actionable information that can be used to evaluate the performance of Oncopeptides over time and compare it to other companies across industries.| Return On Equity | -1.29 | |||
| Return On Asset | -0.67 | |||
| Target Price | 26.67 | |||
| Number Of Employees | 40 | |||
| Beta | -0.67 |
Oncopeptides Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Oncopeptides's current stock value. Our valuation model uses many indicators to compare Oncopeptides value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oncopeptides competition to find correlations between indicators driving Oncopeptides's intrinsic value. More Info.Oncopeptides AB is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Oncopeptides' earnings, one of the primary drivers of an investment's value.Oncopeptides AB Systematic Risk
Oncopeptides' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Oncopeptides volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Oncopeptides AB correlated with the market. If Beta is less than 0 Oncopeptides generally moves in the opposite direction as compared to the market. If Oncopeptides Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Oncopeptides AB is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Oncopeptides is generally in the same direction as the market. If Beta > 1 Oncopeptides moves generally in the same direction as, but more than the movement of the benchmark.
Oncopeptides November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Oncopeptides help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Oncopeptides AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of Oncopeptides AB based on widely used predictive technical indicators. In general, we focus on analyzing Oncopeptides Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Oncopeptides's daily price indicators and compare them against related drivers.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 34.67 | |||
| Value At Risk | (3.69) | |||
| Potential Upside | 3.83 |
Additional Tools for Oncopeptides Stock Analysis
When running Oncopeptides' price analysis, check to measure Oncopeptides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncopeptides is operating at the current time. Most of Oncopeptides' value examination focuses on studying past and present price action to predict the probability of Oncopeptides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncopeptides' price. Additionally, you may evaluate how the addition of Oncopeptides to your portfolios can decrease your overall portfolio volatility.